Debra BorchardtApril 18, 2025
The company said it believes it has enough funding for the next year.
Tag: Psyence Group
Debra BorchardtApril 18, 2025
Adam JacksonSeptember 24, 2024
The sale aligns with Psyence Group's latest lean towards an asset-light business model.
Adam JacksonMarch 11, 2024
The new Nasdaq-listed entity trades under the ticker symbol PBM.
Adam JacksonFebruary 28, 2024
The firm has a negative working capital of nearly $1 million.
Debra BorchardtJanuary 16, 2024
Psyence Group Inc. (CSE: PSYG) reported that its subsidiary, Psyence Biomedical Ltd. issued four senior secured convertible notes to raise $10 million. The deal is concurrent with the closing of a deal with the SPAC (special purpose acquisition company) Newcourt Acquisition Corp (Nasdaq: NCAC) for a new business combination. The new company will receive $2.5 […]
John SchroyerNovember 16, 2023
Psyence also reported earnings for the second quarter ended Sept. 30.
Adam JacksonJuly 28, 2023The losses primarily stem from a surge in research and development costs.
Adam JacksonJuly 12, 2023Psyence stretched its fiscal runway and paid off all the debt on its balance sheet.
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.